The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

Also called NCT06763055

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06763055
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06763055. Randomized; single masking; primary purpose treatment. Start 2025-02-27 (actual); primary completion 2028-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL
Acronym
INTERACT5
Condition
Intracerebral Hemorrhage
Condition
Spontaneous Intracerebral Hemorrhage
Condition
Supratentorial Intracerebral Haemorrhage
Condition
Acute Intracerebral Haemorrhage
Condition
Acute Stroke
Intervention (Drug)
Colchicine 0.5 mg
Intervention (Drug)
Deferoxamine Mesylate
Intervention (Other)
Control (Standard treatment)
Lead sponsor
The George Institute (class: other)
Collaborator
University of Calgary (class: other)

Record details

Record id
cardio:ct-nct06763055
Content hash
e046386cf419c2c81301e0a57b1b0f3d16bdce9677eb60e1e9d76cfa8e58f747